文献速递类风湿关节炎

类风湿关节炎患者对生物制剂改善病情抗风湿药减量的看法:一项混合方法研究

The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

本研究采用混合方法设计,通过半结构化访谈识别影响类风湿关节炎患者考虑生物制剂改善病情抗风湿药减量(逐渐减停)的因素,并用最大差异量表问卷对30个因素进行排序,同时考察患者特征对排序的影响。访谈纳入22例、问卷纳入192例患者。多数受访者对减量持积极态度,患者最关注减量可能导致影响日常生活的疾病复发,以及减量失败后能否恢复剂量并重新有效。

要点

  • 多数受访类风湿关节炎患者对生物制剂改善病情抗风湿药减量持积极态度。
  • 患者担心减量会导致影响日常生活(疼痛、功能)的疾病复发。
  • 患者重视风湿科医生的意见,并希望参与开始减量的决策。

核心结论

  • 本研究结果有助于实施生物制剂改善病情抗风湿药减量,告知照护者患者所关注的问题,并为共享决策提供依据。

研究设计与样本

  • 采用混合方法设计,通过半结构化访谈识别影响因素,并使用最大差异量表问卷对这些因素进行排序。
  • 子研究1纳入22例类风湿关节炎患者进行访谈分析,子研究2纳入192例类风湿关节炎患者进行问卷调查分析。

主要发现

  • 从访谈中识别出30个因素,归纳为9个主题,并在问卷中进行评价。
  • 多数受访者对生物制剂改善病情抗风湿药减量持积极态度。
  • 患者担心减量会导致影响日常生活(疼痛、功能)的疾病复发。
  • 患者认为重要的是知道如果(进一步)减量失败可以增加剂量,且生物制剂改善病情抗风湿药会再次有效。
  • 患者重视风湿科医生的意见,参与开始减量的决策也排名很高;最重要的因素在不同患者组间保持一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to identify the factors that play a role for patients with RA when considering dose reduction (i.e. gradual tapering until discontinuation) of biological DMARDs (bDMARDs), and to determine their relative importance. METHODS: A mixed methods design was used in which we identified influencing factors by performing semi-structured interviews and ranked these factors using a Maximum Difference Scaling questionnaire. Also, we looked at the influence of several patient characteristics on this ranking. RESULTS: For sub study 1 and 2, 22 and 192 patients with RA were included, respectively, in the analyses. Thirty factors were identified from the interviews-characterized into nine themes-and appraised in the questionnaire. Most respondents had a positive attitude towards bDMARD dose reduction. The study showed that patients are concerned that dose reduction will lead to a disease flare that affects their daily life (pain, function). It is important for them to know that it is possible to increase the dose if (further) reduction fails and that the bDMARD will be effective again. Patients value the opinion of their rheumatologist, and being involved in the decision to start tapering is highly ranked as well. The most important factors were consistent between different groups of patients. CONCLUSION: The results from this study facilitate implementation of bDMARD dose reduction; they inform care providers on what is important for patients and provide a basis for shared decision making.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Verhoef LM, Selten EMH, Vriezekolk JE, et al. The patient perspective on biologic DMARD dose reduction in rheumatoid arthritis: a mixed methods study. Rheumatology (Oxford). 2018. PMID: 30010899. doi:10.1093/rheumatology/key205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。